EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial

Shengde Li, Haizhou Hu, Dingding Zhang, Bin Liu, Mengfei Zhong, Lihua Wang, Qingsong Yang, Ping Zhang, Weili Zhao, Fengli Zhao, Yufeng Tang, Xiaoli Wang und 23 weitere

The Lancet Regional Health - Western Pacific · 2026-10 · 75 · 101995

DOI: 10.1016/j.lanwpc.2026.101995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Regional Health - Western Pacific, 2026-10. Verfasst von Shengde Li und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, Beijing Municipal Health Commission, Chinese Academy of Medical Sciences & Peking Union Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tirofiban is sometimes used empirically for branch atheromatous disease (BAD)-related stroke, but its benefit in this population remains unclear. This study aimed to assess the efficacy and safety of intravenous tirofiban administered within 48 h of onset in patients with acute BAD-related stroke.

Methods

This multicentre, randomized, open-label, blinded-endpoint clinical trial enrolled patients with BAD-related stroke within 48 h of onset from 25 hospitals in China between 9 November 2023 and 22 November 2025. Eligible patients were randomly assigned to the tirofiban group (intravenously, 0.4 μg/kg per minute for 30 min, followed by a 0.1 μg/kg per minute for 47.5 h) or standard antiplatelet therapy group (oral aspirin with or without clopidogrel) for 48 h. The primary endpoint was an excellent functional outcome, defined as a score of 0 or 1 on the modified Rankin Scale at 90 days. Safety outcomes included major bleeding within 90 days. This trial was registered on ClinicalTrials.gov (NCT06037889).

Findings

Among 516 patients randomized, 513 were included in the primary analysis (258 with tirofiban and 255 with standard antiplatelet therapy). An excellent functional outcome was observed in 181 of 258 patients (70.2%) in the tirofiban group and 178 of 255 (69.8%) in the standard antiplatelet therapy group (risk ratio, 1.01 [95% CI, 0.90-1.13]; P = 0.93). Major bleeding occurred in 0 of 259 participants in the tirofiban-exposed safety population and 1 of 245 (0.4%) in the standard-antiplatelet-exposed safety population.

Interpretation

Among patients with acute BAD-related stroke, intravenous tirofiban administered within 48 h of onset without concomitant oral antiplatelet therapy was not superior to standard antiplatelet therapy for achieving an excellent functional outcome at 90 days. These findings should not be extrapolated to substantially earlier treatment or to other tirofiban-based antiplatelet strategies. Funding: National High Level Hospital Clinical Research Funding, Capital's Funds for Health Improvement and Research, CAMS Innovation Fund for Medical Sciences (CIFMS), Noncommunicable Chronic Diseases-National Science and Technology Major Project, and China Shijiazhuang Pharmaceutical Company (CSPC) NBP Pharmaceurical Co., Ltd.

Schlagwörter

Stichwörter der Autor:innen

Branch atheromatous diseaseMagnetic resonance imageTherapyTirofiban

Autor:innen und Institutionen

  • Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
  • Center for Prevention and Early Intervention, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Uni…
  • First Department of Neurology, The Affiliated Hospital of North China University of Science and Technology, Tangshan, China.
  • Department of Neurology, Shengli Oilfield Central Hospital, Dongying, China.
  • Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Department of Neurology, The First People's Hospital of Shangqiu, Shangqiu, China.

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • Beijing Municipal Health Commission
  • Chinese Academy of Medical Sciences & Peking Union Medical College
  • Innovation Fund
  • Peking Union Medical College Hospital
  • National Science and Technology Major Project

Zitieren

APA

Li, S., Hu, H., Zhang, D., Liu, B., Zhong, M., Wang, L., Yang, Q., Zhang, P., Zhao, W., Zhao, F., Tang, Y., Wang, X., Li, H., Chen, L., Chen, G., Wang, R., Dong, A., Zheng, Z., Wang, X., …, & BRANT Investigators (2026). Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial. The Lancet Regional Health - Western Pacific, 75, 101995. https://doi.org/10.1016/j.lanwpc.2026.101995

Vancouver

Li S, Hu H, Zhang D, Liu B, Zhong M, Wang L, et al. Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial. The Lancet Regional Health - Western Pacific. 2026;75:101995. doi:10.1016/j.lanwpc.2026.101995

BibTeX
@article{Li2026,
  author = {Li, Shengde and Hu, Haizhou and Zhang, Dingding and Liu, Bin and Zhong, Mengfei and Wang, Lihua and Yang, Qingsong and Zhang, Ping and Zhao, Weili and Zhao, Fengli and Tang, Yufeng and Wang, Xiaoli and Li, Heng and Chen, Liwei and Chen, Guofang and Wang, Rui and Dong, Aiqin and Zheng, Zhidong and Wang, Xiaona and Liu, Qin and Zhang, Jiangtao and Wang, Jiacai and Wang, Li and Li, Xin and Chen, Hong and Ma, Junfang and Zhao, Yuhua and Sha, Yuhui and Nguyen, Thanh and Wang, Duolao and Zhou, Lixin and Zhu, Yicheng and Peng, Bin and Ni, Jun and BRANT Investigators, BRANT Investigators},
  title = {Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial},
  journal = {The Lancet Regional Health - Western Pacific},
  year = {2026},
  volume = {75},
  pages = {101995},
  doi = {10.1016/j.lanwpc.2026.101995}
}
Kostenlos starten →